Abstract Details

Title Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer's disease

Topic Aging and Dementia

Presentation(s) S2 - (-)

Poster/Presentation
Number 004

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Samantha Budd Haeberlein PRESENTER	Samantha Budd Haeberlein has received personal compensation for serving as an employee of Biogen. An immediate family member of Samantha Budd Haeberlein has received personal compensation for serving as an employee of Alkermes. Samantha Budd Haeberlein has received stock or an ownership interest from Biogen.
Sarah Gheuens, MD	No disclosure on file
Tianle Chen, PhD	Dr. Chen has received personal compensation for serving as an employee of Biogen.
	No disclosure on file
Sebastian F. Von Rosenstiel, MD, PhD (Takeda)	No disclosure on file
Ping Chiao, MD (Biogen Idec)	No disclosure on file
	No disclosure on file
Christian Von Hehn, MD, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
Roger Nitsch, MD (University of Zurich, Division of Psychiatry)	No disclosure on file
Alfred W. Sandrock, MD, PhD (Biogen)	No disclosure on file